PDCD1 and neoplasm: In an EMT-6 mammary carcinoma model IL-21 and mAb CTLA-4 combination therapy induced complete regression in half of the mice and noticeable delays in tumor growth for the rest of mice employed in the study, while the combination of IL-21 and mAb PD-1 displayed no noticeable effects.